BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

625 related articles for article (PubMed ID: 29659569)

  • 21. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
    Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
    Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.
    Southey MC; Goldgar DE; Winqvist R; Pylkäs K; Couch F; Tischkowitz M; Foulkes WD; Dennis J; Michailidou K; van Rensburg EJ; Heikkinen T; Nevanlinna H; Hopper JL; Dörk T; Claes KB; Reis-Filho J; Teo ZL; Radice P; Catucci I; Peterlongo P; Tsimiklis H; Odefrey FA; Dowty JG; Schmidt MK; Broeks A; Hogervorst FB; Verhoef S; Carpenter J; Clarke C; Scott RJ; Fasching PA; Haeberle L; Ekici AB; Beckmann MW; Peto J; Dos-Santos-Silva I; Fletcher O; Johnson N; Bolla MK; Sawyer EJ; Tomlinson I; Kerin MJ; Miller N; Marme F; Burwinkel B; Yang R; Guénel P; Truong T; Menegaux F; Sanchez M; Bojesen S; Nielsen SF; Flyger H; Benitez J; Zamora MP; Perez JI; Menéndez P; Anton-Culver H; Neuhausen S; Ziogas A; Clarke CA; Brenner H; Arndt V; Stegmaier C; Brauch H; Brüning T; Ko YD; Muranen TA; Aittomäki K; Blomqvist C; Bogdanova NV; Antonenkova NN; Lindblom A; Margolin S; Mannermaa A; Kataja V; Kosma VM; Hartikainen JM; Spurdle AB; Investigators K; ; Wauters E; Smeets D; Beuselinck B; Floris G; Chang-Claude J; Rudolph A; Seibold P; Flesch-Janys D; Olson JE; Vachon C; Pankratz VS; McLean C; Haiman CA; Henderson BE; Schumacher F; Le Marchand L; Kristensen V; Alnæs GG; Zheng W; Hunter DJ; Lindstrom S; Hankinson SE; Kraft P; Andrulis I; Knight JA; Glendon G; Mulligan AM; Jukkola-Vuorinen A; Grip M; Kauppila S; Devilee P; Tollenaar RA; Seynaeve C; Hollestelle A; Garcia-Closas M; Figueroa J; Chanock SJ; Lissowska J; Czene K; Darabi H; Eriksson M; Eccles DM; Rafiq S; Tapper WJ; Gerty SM; Hooning MJ; Martens JW; Collée JM; Tilanus-Linthorst M; Hall P; Li J; Brand JS; Humphreys K; Cox A; Reed MW; Luccarini C; Baynes C; Dunning AM; Hamann U; Torres D; Ulmer HU; Rüdiger T; Jakubowska A; Lubinski J; Jaworska K; Durda K; Slager S; Toland AE; Ambrosone CB; Yannoukakos D; Swerdlow A; Ashworth A; Orr N; Jones M; González-Neira A; Pita G; Alonso MR; Álvarez N; Herrero D; Tessier DC; Vincent D; Bacot F; Simard J; Dumont M; Soucy P; Eeles R; Muir K; Wiklund F; Gronberg H; Schleutker J; Nordestgaard BG; Weischer M; Travis RC; Neal D; Donovan JL; Hamdy FC; Khaw KT; Stanford JL; Blot WJ; Thibodeau S; Schaid DJ; Kelley JL; Maier C; Kibel AS; Cybulski C; Cannon-Albright L; Butterbach K; Park J; Kaneva R; Batra J; Teixeira MR; Kote-Jarai Z; Olama AA; Benlloch S; Renner SP; Hartmann A; Hein A; Ruebner M; Lambrechts D; Van Nieuwenhuysen E; Vergote I; Lambretchs S; Doherty JA; Rossing MA; Nickels S; Eilber U; Wang-Gohrke S; Odunsi K; Sucheston-Campbell LE; Friel G; Lurie G; Killeen JL; Wilkens LR; Goodman MT; Runnebaum I; Hillemanns PA; Pelttari LM; Butzow R; Modugno F; Edwards RP; Ness RB; Moysich KB; du Bois A; Heitz F; Harter P; Kommoss S; Karlan BY; Walsh C; Lester J; Jensen A; Kjaer SK; Høgdall E; Peissel B; Bonanni B; Bernard L; Goode EL; Fridley BL; Vierkant RA; Cunningham JM; Larson MC; Fogarty ZC; Kalli KR; Liang D; Lu KH; Hildebrandt MA; Wu X; Levine DA; Dao F; Bisogna M; Berchuck A; Iversen ES; Marks JR; Akushevich L; Cramer DW; Schildkraut J; Terry KL; Poole EM; Stampfer M; Tworoger SS; Bandera EV; Orlow I; Olson SH; Bjorge L; Salvesen HB; van Altena AM; Aben KK; Kiemeney LA; Massuger LF; Pejovic T; Bean Y; Brooks-Wilson A; Kelemen LE; Cook LS; Le ND; Górski B; Gronwald J; Menkiszak J; Høgdall CK; Lundvall L; Nedergaard L; Engelholm SA; Dicks E; Tyrer J; Campbell I; McNeish I; Paul J; Siddiqui N; Glasspool R; Whittemore AS; Rothstein JH; McGuire V; Sieh W; Cai H; Shu XO; Teten RT; Sutphen R; McLaughlin JR; Narod SA; Phelan CM; Monteiro AN; Fenstermacher D; Lin HY; Permuth JB; Sellers TA; Chen YA; Tsai YY; Chen Z; Gentry-Maharaj A; Gayther SA; Ramus SJ; Menon U; Wu AH; Pearce CL; Van Den Berg D; Pike MC; Dansonka-Mieszkowska A; Plisiecka-Halasa J; Moes-Sosnowska J; Kupryjanczyk J; Pharoah PD; Song H; Winship I; Chenevix-Trench G; Giles GG; Tavtigian SV; Easton DF; Milne RL
    J Med Genet; 2016 Dec; 53(12):800-811. PubMed ID: 27595995
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growing recognition of the role for rare missense substitutions in breast cancer susceptibility.
    Tavtigian SV; Chenevix-Trench G
    Biomark Med; 2014; 8(4):589-603. PubMed ID: 24796624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer.
    Ryu JS; Lee HY; Cho EH; Yoon KA; Kim MK; Joo J; Lee ES; Kang HS; Lee S; Lee DO; Lim MC; Kong SY
    Cancer Sci; 2020 Oct; 111(10):3912-3925. PubMed ID: 32761968
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
    Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
    JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rare key functional domain missense substitutions in MRE11A, RAD50, and NBN contribute to breast cancer susceptibility: results from a Breast Cancer Family Registry case-control mutation-screening study.
    Damiola F; Pertesi M; Oliver J; Le Calvez-Kelm F; Voegele C; Young EL; Robinot N; Forey N; Durand G; Vallée MP; Tao K; Roane TC; Williams GJ; Hopper JL; Southey MC; Andrulis IL; John EM; Goldgar DE; Lesueur F; Tavtigian SV
    Breast Cancer Res; 2014 Jun; 16(3):R58. PubMed ID: 24894818
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A study of over 35,000 women with breast cancer tested with a 25-gene panel of hereditary cancer genes.
    Buys SS; Sandbach JF; Gammon A; Patel G; Kidd J; Brown KL; Sharma L; Saam J; Lancaster J; Daly MB
    Cancer; 2017 May; 123(10):1721-1730. PubMed ID: 28085182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2.
    Kraus C; Hoyer J; Vasileiou G; Wunderle M; Lux MP; Fasching PA; Krumbiegel M; Uebe S; Reuter M; Beckmann MW; Reis A
    Int J Cancer; 2017 Jan; 140(1):95-102. PubMed ID: 27616075
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ten genes for inherited breast cancer.
    Walsh T; King MC
    Cancer Cell; 2007 Feb; 11(2):103-5. PubMed ID: 17292821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Germline mutations in a DNA repair pathway are associated with familial colorectal cancer.
    Xu P; Sun D; Gao Y; Jiang Y; Zhong M; Zhao G; Chen J; Wang Z; Liu Q; Hong J; Chen H; Chen YX; Fang JY
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34549727
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer.
    Wong MW; Nordfors C; Mossman D; Pecenpetelovska G; Avery-Kiejda KA; Talseth-Palmer B; Bowden NA; Scott RJ
    Breast Cancer Res Treat; 2011 Jun; 127(3):853-9. PubMed ID: 21409391
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunohistochemical findings and clinicopathological features of breast cancers with pathogenic germline mutations in Non-BRCA genes.
    Singh K; Scalia J; Legare R; Quddus MR; Sung CJ
    Hum Pathol; 2024 Apr; 146():49-56. PubMed ID: 38608781
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implementation of next-generation sequencing for molecular diagnosis of hereditary breast and ovarian cancer highlights its genetic heterogeneity.
    Pinto P; Paulo P; Santos C; Rocha P; Pinto C; Veiga I; Pinheiro M; Peixoto A; Teixeira MR
    Breast Cancer Res Treat; 2016 Sep; 159(2):245-56. PubMed ID: 27553368
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline pathogenic variants in PALB2 and other cancer-predisposing genes in families with hereditary diffuse gastric cancer without CDH1 mutation: a whole-exome sequencing study.
    Fewings E; Larionov A; Redman J; Goldgraben MA; Scarth J; Richardson S; Brewer C; Davidson R; Ellis I; Evans DG; Halliday D; Izatt L; Marks P; McConnell V; Verbist L; Mayes R; Clark GR; Hadfield J; Chin SF; Teixeira MR; Giger OT; Hardwick R; di Pietro M; O'Donovan M; Pharoah P; Caldas C; Fitzgerald RC; Tischkowitz M
    Lancet Gastroenterol Hepatol; 2018 Jul; 3(7):489-498. PubMed ID: 29706558
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Martín-Morales L; Garre P; Lorca V; Cazorla M; Llovet P; Bando I; García-Barberan V; González-Morales ML; Esteban-Jurado C; de la Hoya M; Castellví-Bel S; Caldés T
    Cancer Prev Res (Phila); 2021 Feb; 14(2):185-194. PubMed ID: 33115781
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Germline variants in pancreatic cancer patients with a personal or family history of cancer fulfilling the revised Bethesda guidelines.
    Ohmoto A; Morizane C; Kubo E; Takai E; Hosoi H; Sakamoto Y; Kondo S; Ueno H; Shimada K; Yachida S; Okusaka T
    J Gastroenterol; 2018 Oct; 53(10):1159-1167. PubMed ID: 29667044
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double heterozygotes among breast cancer patients analyzed for BRCA1, CHEK2, ATM, NBN/NBS1, and BLM germ-line mutations.
    Sokolenko AP; Bogdanova N; Kluzniak W; Preobrazhenskaya EV; Kuligina ES; Iyevleva AG; Aleksakhina SN; Mitiushkina NV; Gorodnova TV; Bessonov AA; Togo AV; Lubiński J; Cybulski C; Jakubowska A; Dörk T; Imyanitov EN
    Breast Cancer Res Treat; 2014 Jun; 145(2):553-62. PubMed ID: 24800916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Frequency of heterozygous germline pathogenic variants in genes for Fanconi anemia in patients with non-BRCA1/BRCA2 breast cancer: a meta-analysis.
    Alter BP; Best AF
    Breast Cancer Res Treat; 2020 Jul; 182(2):465-476. PubMed ID: 32488392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan.
    Rashid MU; Khan FA; Muhammad N; Loya A; Hamann U
    Cancer Res Treat; 2019 Jul; 51(3):992-1000. PubMed ID: 30309218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of pathogenic germline mutation in CHEK2, PALB2, MRE11, and RAD50 in patients at high risk for hereditary breast cancer.
    Kim H; Cho DY; Choi DH; Oh M; Shin I; Park W; Huh SJ; Nam SJ; Lee JE; Kim SW
    Breast Cancer Res Treat; 2017 Jan; 161(1):95-102. PubMed ID: 27783279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.